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Abstract
Background: To evaluate the diagnostic accuracy of clinical signs and symptoms, C-reactive
protein (CRP) and spirometric parameters and determine their interrelation in patients suspected
to have an obstructive airway disease (OAD) in primary care.
Methods: In a cross sectional diagnostic study, 60 adult patients coming to the general practitioner
(GP) for the first-time with complaints suspicious for obstructive airway disease (OAD) underwent
spirometry. Peak expiratory flow (PEF)-variability within two weeks was determined in patients
with inconspicuous spirometry. Structured medical histories were documented and CRP was
measured. The reference standard was the Tiffeneau ratio (FEV1/VC) in spirometry and the PEF-
variability. OAD was diagnosed when FEV1/VC ≤ 70% or PEF-variability > 20%.
Results: 37 (62%) patients had OAD. The best cut-off value for CRP was found at 2 mg/l with a
diagnostic odds ratio (OR) of 4.4 (95% CI 1.4–13.8). Self-reported wheezing was significantly
related with OAD (OR 3.4; CI 1.1–10.3), whereas coughing was inversely related (OR 0.2; CI 0.1–
0.7). The diagnostic OR of CRP increased when combined with dyspnea (OR 8.5; 95% CI 1.7–42.3)
or smoking history (OR 8.4; 95% CI 1.5–48.9). CRP (p = 0.004), FEV1 (p = 0.001) and FIV1 (p =
0.023) were related with the severity of dyspnea. CRP increased with the number of cigarettes,
expressed in pack years (p = 0.001).
Conclusion: The diagnostic accuracy of clinical signs and symptoms was low. The diagnostic
accuracy of CRP improved in combination with dyspnea and smoking history. Due to their
coherence with the severity of dyspnea and number of cigarettes respectively, CRP and spirometry
might allow risk stratification of patients with OAD in primary care. Further studies need to be
done to confirm these findings.
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Background
The impact of obstructive airway diseases (OAD) is
increasing, leading to high disability and mortality [1].
Consequently, optimal diagnostic performance is becom-
ing an increasing challenge in primary care [2]. Medical
history taking and physical examination deliver impor-
tant information for diagnosing obstructive airway dis-
eases (OAD) in primary care, but their predictive values
are weak [3,4]. Attempts were made to improve the diag-
nostic accuracy in this field, like the single measurement
of peak expiratory flow (PEF) and the use of screening
questionnaires [5,6], but their sensitivities or specificities
were low. Therefore, it would be helpful to find additional
clinical markers to identify patients with risk for having an
obstructive airway disease and to estimate their severity of
the disease. One useful predictor for OAD could be C-
reactive protein (CRP), as it is related with irreversible air-
way obstruction [7] due to some kind of systemic inflam-
mation [8].
However, the core of diagnostics is the spirometry and
many efforts are done to implement its use in primary care
[9,10]. Consequently, spirometers are increasingly availa-
ble in general practice, and modern instruments are not
only measuring FEV1 (forced expiratory volume in one
second) and VC (vital capacity), but also inspiratory
parameters. Inspiratory parameters could be of value for
the assessment of the disease, as FIV1 (forced inspiratory
volume in one second) was shown to be related with the
severity of dyspnea [11,12]. The aim of the present study
was to determine the diagnostic accuracy of clinical signs
and symptoms and CRP for diagnosing airway obstruc-
tion in primary care. A secondary aim was to identify pre-
dictors for the severity of the disease by analyzing the
relation between clinical signs and symptoms, CRP and
spirometric parameters.
Methods
Design
This cross sectional diagnostic study was performed
between October 2003 and May 2004 in six general prac-
tices. The results from spirometry (FEV1/VC = Tiffeneau-
Quotient) and the variability of PEF-measurement within
two weeks were used as a reference standard.
Participants
Sixty adult patients coming to the general practitioner for
the first-time with complaints leading to the assumption
of some kind of OAD were included consecutively. They
presented symptoms like dyspnea, coughing, expectora-
tion or self-reported wheezing. The patients have not been
diagnosed earlier for OAD and they have not received any
anti-obstructive medicine before. Other exclusion criteria
related to well known side effects of inhaled sympathom-
imetics, namely untreated hyperthyreosis, unstable coro-
nary artery disease or cardiac arrhythmia. Pregnancy also
leads to exclusion. The study was approved by the Medical
Ethics Committee of the University Heidelberg. Patients
gave written informed consent.
Measurements
Medical history was taken with a structured interview sim-
ilar to the asthma screening questionnaire of the Euro-
pean Community Respiratory Health Survey (ECRHS)
[13]. This questionnaire was designed to assess the preva-
lence of asthma (= reversible OAD) in several European
Table 1: Characteristics of the study population Values are numbers (proportion) or mean (SD); OAD = obstructive airway disease
Overall No OAD or 
restrictive pattern
Reversible 
OAD
Not reversible 
OAD
n (%) n (%) n (%) n (%)
Total study population 60 (100) 23 (38) 27 (45) 10 (17)
Female 40 (67) 15 (65) 19 (70) 6 (60)
Age [mean (SD)] 46 (18) 42 (18) 46 (17) 54 (18)
Have you had wheezing in your chest (yes) 39 (65) 11 (48) 22 (82) 6 (60)
Do you sometimes have dyspnea (yes) 35 (58) 12 (52) 16 (59) 7 (70)
Do you often cough (yes) 26 (43) 15 (65) 9 (33) 2 (20)
Do you often have expectoration (yes) 22 (37) 7 (30) 11 (41) 4 (40)
Wheezing when not having a cold (yes) 25 (42) 7 (30) 15 (56) 3 (30)
Breathless when wheezing was present (yes) 22 (37) 7 (30) 11 (41) 4 (40)
Have you been woken up with a feeling of tightness in your chest (yes) 14 (23) 6 (26) 5 (19) 3 (30)
Have you been woken up by an attack of dyspnea (yes) 13 (22) 6 (26) 7 (26) 0 (0)
Have you been woken up by an attack of coughing (yes) 39 (65) 16 (70) 17 (63) 6 (60)
Do you have any nasal allergies (yes) 25 (42) 10 (43) 12 (44) 3 (30)
Do you often have common cold (yes) 22 (37) 8 (35) 8 (30) 6 (60)
Does it often take longer than 10 days to recover from a common cold (yes) 29 (48) 10 (43) 12 (44) 7 (70)
Do you smoke/Did you smoke (yes) 35 (58) 12 (52) 16 (59) 7 (70)
How much do you smoke [mean in pack year (SD)] 13 (15) 13 (10) 9 (10) 21 (26)BMC Family Practice 2006, 7:28 http://www.biomedcentral.com/1471-2296/7/28
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areas. The interview was expanded to symptoms of COPD
(= irreversible OAD) (table 1). Patients were asked for the
severity of their dyspnea, categorized as dyspnea at rest
(severe); dyspnea while walking straight ahead (moder-
ate); dyspnea while taking the stairs of two floors (mild)
and no dyspnea. Patients were questioned about their
smoking habits, allowing calculation of the number of
pack years (= [years of smoking: 20] × number of daily cig-
arettes). The physician performed the physical examina-
tion, always including auscultation of the patients' lungs.
All findings were documented and checked for complete-
ness.
Spirometry was performed in the general practices by two
research assistants, who were initially trained at the pul-
monary outpatient clinic of the University Hospital of
Heidelberg. In case of an unacceptable flow-volume
curve, the spirometric software gave an error message. The
best of three consecutive spirometry recordings was used,
according to the guidelines of the American Thoracic Soci-
ety (ATS) [14]. The maximal inspiratory and expiratory
flow volume curves were generated by forced deep inspi-
ration and expiration with short intervening periods of
tidal breathing. The forced inspiratory manoeuvres were
always done after forced expiratory manoeuvres.
Every patient received a bronchodilation test with an
additional performance of spirometry 20 minutes after
inhaling Salbutamol through a spacer. An obstructive air-
way disease was diagnosed if FEV1/VC  ≤ 70%. The
obstruction was classified as not reversible on Salbuta-
mol, if the bronchodilation response ∆ FEV1 was below
12% of the baseline and below 200 ml [15]. Blood was
taken after the spirometry manoeuvre for determining
CRP, which was assessed with an automated chemilumi-
nometric assay kit.
Patients with no signs of airway obstruction after the
results of the spirometry (i.e. FEV1/VC > 70%) received a
PEF-meter (Vitalograph®) in order to perform PEF-meas-
urements twice daily for 14 days. The patients were
trained in performing this maneuver and documented the
results in a diary. If the variability ((highest value - lowest
value)/highest value) within these two weeks was above
20 %, reversible airway obstruction (= asthma) was diag-
nosed according to the international asthma guidelines
[15]. The final diagnosis (reference standard) was con-
firmed by the main investigator (A.S.) and the pulmonol-
ogist (J.M.), who were kept unaware of the measured
inspiratory parameters and CRP.
Data analysis
As the sensitivities and specificities of clinical signs and
symptoms and spirometric parameters are yet unknown
for OAD diagnosed in primary care, a proper power calcu-
lation could not be performed. The data were analyzed
with SPSS 11.0 for Windows.
The CRP values were log-transformed and entered the
ROC-analyses to assess the best cut-off point. Sensitivity,
specificity, and predictive values were calculated from 2 ×
2 tables at the best cut-off-point. The best cut-off-point
was chosen at the highest sum of positive and negative
predictive value (PPV and NPV). CRP and clinical signs
and symptoms were compared with the reference out-
comes of spirometry and PEF-protocol. 95% confidence
intervals were calculated using Wilson's method [16].
Binary logistic regression was done to estimate the diag-
nostic odds ratios (OR) of CRP and clinical signs and
symptoms (as independent variables) for the presence of
OAD (as dependent variable). Positive likelihood ratios
(LR+) were calculated to receive the ratio of abnormal
findings in ill and healthy patients. Negative likelihood
ratios (LR-) were calculated for the ratio of normal find-
ings in ill and healthy patients. 95% confidence intervals
were derived from the log method [17].
In subgroup analyses, diagnostic values of CRP were cal-
culated in combination with dyspnea, smoking history,
coughing, expectoration, wheezing and abnormal finding
in auscultation. In patients with the established diagnosis
of OAD, the relationships between severity of dyspnea,
CRP and spirometric parameters respectively were investi-
gated using Spearman's correlation coefficient (for ordi-
nal variables) and Pearson's correlation coefficient (for
continuous variables).
Results
Study population
Two-thirds of the 60 patients were female; the average age
was 46 years. 27 (45%) had a reversible OAD, of which 8
were identified by spirometry and 19 through the PEF-
protocol (figure 1).
Ten showed an airway obstruction irreversible after inha-
lation of Salbutamol; one patient had a restrictive pattern.
Fourteen (23%) patients with PEF-variability below 20 %
within two weeks did not show abnormal signs in spirom-
etry. Eight (13%) patients with inconspicuous spirometry
did not bring back the PEF-protocol, assuring that they
had no problems anymore. Thus, in total 37 (62%) did
have OAD, whereas 23 (38%) patients were diagnosed as
not having OAD.
The patients without OAD were four years younger than
those with reversible OAD and the latter ones were eight
years younger than those with not reversible OAD (table
1). The patients complained most frequently about
wheezing (65%) and dyspnea (58%), coughing (43%)
and expectoration (37%). Dyspnea and expectorationBMC Family Practice 2006, 7:28 http://www.biomedcentral.com/1471-2296/7/28
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were mainly associated with OAD, whereas coughing was
related with not having OAD. Wheezing was more pro-
nounced for those having OAD. Waking up by an attack
of coughing seems not to distinguish healthy from ill
patients, as there is a similar distribution in all patients.
Patients with non-reversible OAD seem to have a com-
mon cold (60%) more often, taking more than 10 days for
recovering (70%). These patients also had the highest
tobacco use (21 pack years). Those with reversible OAD
had the lowest use (9 pack years).
Diagnostic value of CRP and clinical signs and symptoms
The best cut-off point for CRP was at 2 mg/l, showing a
diagnostic OR of 4.4 (table 2). The five symptoms with
Table 2: Sensitivities (sens), specificities (spec), positive and negative predictive values (PPV and NPV), odds ratios (OR) and likelihood 
ratios (LR+ and LR-) of clinical signs and symptoms and C-reactive protein (CRP) for the presence of obstructive airway disease (n = 
60)
Signs/Symptoms Sens 95% CI Spec 95% CI PPV 95% CI NPV 95% CI OR 95% CI LR + 95% CI LR - 95% CI
CRP > 2 mg/l 62.2 46.1–75.9 72.7 51.9–86.9 79.3 61.6–90.2 53.3 36.1–69.8 4.4 1.4–13.8 2.3 1.1–4.7 0.5 0.3–0.8
Dyspnea 62.2 46.1–75.9 47.8 29.2–67.0 65.7 49.2–79.2 44.0 26.7–62.9 1.5 0.5–4.3 1.2 0.8–1.9 0.8 0.4–1.4
Coughing 29.7 17.5–45.8 34.8 18.8–55.1 42.3 25.5–61.1 23.5 12.4–40.0 0.2 0.1–0.7 0.5 0.3–0.8 2.0 1.1–3.7
Expectoration 40.5 26.3–56.5 69.7 49.1–84.4 68.2 47.3–83.6 42.1 27.9–57.8 1.6 0.5–4.7 1.3 0.6–2.8 0.9 0.6–1.3
Wheezing 75.7 59.9–86.6 52.2 33.0–70.8 71.8 56.2–83.5 57.1 36.5–75.5 3.4 1.1–10.3 1.6 1.0–2.5 0.5 0.2–0.9
Smoking history 62.2 46.1–75.9 52.2 29.2–67.0 65.7 49.2–79.2 44.0 26.7–62.9 0.7 0.2–1.9 1.2 0.8–1.9 0.8 0.4–1.4
Auscultation 27.8 15.8–44.0 87.0 67.9–95.5 76.9 49.7–91.8 43.5 30.2–57.8 2.6 0.6–10.6 2.1 0.7–6.9 0.8 0.6–1.1
Flow chart of inclusion and diagnostic work up (OAD = obstructive airway disease; PEF = peak expiratory flow) Figure 1
Flow chart of inclusion and diagnostic work up (OAD = obstructive airway disease; PEF = peak expiratory flow).
patients
with symptoms
60
spirometry without
abnormal findings
41
spirometry
showing obstruction
18
PEF-variability
< 20 %
14
PEF-variability
> 20 %
19
PEF
missing
8
no OAD
22
reversible OAD
27
not reversible OAD
10
bronchodilator
response positive
8
bronchodilator
response negative
10
restrictive
lung disease
1BMC Family Practice 2006, 7:28 http://www.biomedcentral.com/1471-2296/7/28
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the best test characteristics are listed in table 2. Only self
reported wheezing was significantly associated with hav-
ing OAD (OR 3.4), showing a sensitivity of 75.7% and
specificity of 52.2%. The sensitivity of "often coughing"
was only 29.7% and the specificity was 34.8%. Thus,
coughing was negatively related with OAD (OR 0.2).
Moreover, auscultation was not significantly associated
with the diagnosis.
The diagnostic odds ratio of CRP increased when it was
combined with the clinical symptom dyspnea (OR 8.5;
95% CI 1.7–42.3) or a positive smoking history (OR 8.4;
95% CI 1.5–48.9) (not in table). However, confidence
intervals were wide because of small sample sizes (n = 35
in both subgroups). There was no significant improve-
ment when CRP was combined with the other clinical
signs and symptoms.
Relation between severity of dyspnea, smoking history, 
CRP and spirometric parameters
There was a significant association between CRP and the
severity of dyspnea in patients with established diagnosis
(correlation coefficientSpearman [cosp] = 0.46) (table 3).
There was also a significant relationship between severity
of dyspnea and decrease of FEV1 (cosp = -0.52) and FIV1
(cosp = -0.41). CRP increased with the number of pack
years (correlation coefficientPearson = 0.648) (table 4).
Discussion
This study demonstrates the difficulties in diagnosing
obstructive airway diseases in general practice solely on
the basis of clinical signs and symptoms. A combination
of clinical signs and symptoms with CRP had the best
diagnostic accuracy. CRP was related to smoking history;
and it could be shown for the first time that CRP is related
to the severity of dyspnea in patients with OAD. Also FEV1
and FIV1 were associated with the severity of dyspnea.
Only self reported wheezing was positively associated
with the presence of the disease, but the other parameters
of medical history were not accurate for identifying
patients suffering from OAD. These findings are consist-
ent with previous studies [18-20]. Interestingly, coughing
is negatively associated with the presence of OAD. This
might contradict common clinical findings [3], but these
are often derived from selected clinical settings. Coughing
also had a negative association in one survey, pointing out
that this symptom is often attributed to other illnesses
than asthma [18]. The results of auscultation are similar to
those from Strauss et al, who found a positive LR of 2.7 in
his survey. Thus, auscultation could be a difficult marker
when the patient is not symptomatic during the physical
examination.
The relation between CRP and the severity of airway
obstruction in COPD was illustrated before in a popula-
tion based survey, which found an association between
FEV1 and CRP [8]. CRP has attracted more attention over
the last years, as multiple associations with cardiovascular
diseases [21], COPD [7], osteoporosis [22] and even
depression [23] were identified. It is speculated that some
of these diseases are caused by a low grade inflammation
reflected by a small elevation of inflammatory markers
[8], which might indicate a higher prevalence of systemic
complications. Our findings also confirm that there is a
chronic inflammatory process on a low level, since a no
more than slightly elevated CRP (> 2 mg/l) has a signifi-
cant diagnostic OR for OAD. This cut-off-point is in line
Table 4: Relation between smoking history, CRP, FEV1 and FIV1 in patients with airway obstruction
Smoking [pack year] n CRP [mg/l]
mean (sd)
FEV1 [l]
mean (sd)
FEV1pred. [%]
mean (sd)
FIV1 [l]
mean (sd)
0 < py ≤ 5 10 2.9 (1.6) 2.7 (1.0) 79.1 (22.0) 3.2 (0.1)
5 < py ≤ 10 3 3.2 (2.3) 3.0 (0.8) 89.8 (4.8) 3.5 (0.8)
10 < py ≤ 20 6 5.3 (4.2) 3.2 (1.4) 93.6 (14.6) 3.3 (1.1)
py > 20 4 13.7 (8.4) 2.7 (1.4) 82.1 (13.4) 3.3 (2.1)
p 0.001 0.381 0.552 0.147
Table 3: Relation between severity of dyspnea, CRP, FEV1 and FIV1 in patients with airway obstruction
Severity n CRP [mg/l]
mean (sd)
FEV1 [l]
mean (sd)
FEV1pred. [%]
mean (sd)
FIV1 [l]
mean (sd)
Smoking [py]
mean (sd)
No dyspnea 14 2.8 (1.5) 3.4 (1.0) 94.6 (22.7) 3.65 (0.8) 4.4 (6.1)
Mild 16 7.1 (9.2) 2.4 (0.9) 83.8 (16.9) 2.9 (1.1) 9.9 (20.9)
Moderate 2 6.7 (1.1) 1.8 (0.4) 69.0 (21.8) 2.6 (0.1) 5.0 (7.1)
Severe 5 11.6 (13.1) 2.1 (1.1) 82.6 (16.0) 2.5 (1.2) 12.7 (8.2)
P 0.004 0.001 0.079 0.012 0.474
py = pack yearBMC Family Practice 2006, 7:28 http://www.biomedcentral.com/1471-2296/7/28
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with Sin et al. [8] who found their best threshold value for
CRP at 2.2 mg/l. Our finding of a positive association
between CRP and the number of pack years is supported
by Gan et al., who detected that active smoking increases
CRP [24]. They suggested that smoking and reduced FEV1
have an additive effect on systemic inflammation. The
association with the severity of dyspnea and smoking his-
tory might make CRP of interest for risk stratification of
patients with OAD in primary care. The importance of this
has been underlined by Huijnen et al., who identified dys-
pnea as a significant predictor for mortality [25]. Until
now, the diagnostic value of CRP for primary care was
mostly evaluated for acute inflammatory diseases like
lower respiratory tract infection (LRTI) [26] and acute
maxillary sinusitis [27]. In LRTI, CRP has a high diagnos-
tic value in combination with clinical signs and symptoms
[26]. The impact on practice management was demon-
strated as the use of CRP lowered antibiotic prescribing for
sinusitis [28]. In our study the diagnostic odds ratios of
CRP improved in patients with dyspnea or smoking his-
tory. However, the confidence intervals were wide, which
could mainly be due to the small sample size. And it must
be noted additionally that it was not possible to differen-
tiate between asthma and COPD. Therefore, further stud-
ies in larger populations of patients with COPD and
asthma are necessary.
We were the first to demonstrate in primary care that dys-
pnea is correlated with FIV1. This relation was so far only
demonstrated in a highly selected population with
already known COPD [11,12]. Taube et al found, that the
perception of dyspnea is more related to the inspiratory
than expiratory parameters [11]. Thus, FIV1 could also
provide possibilities for risk stratification of patients in
primary care as it is related with the severity of dyspnea.
However, it must be noted for our study, that FEV1 shows
a higher correlation coefficient than FIV1. Therefore the
applicability and specificity of these parameters for pri-
mary care need to be evaluated in further studies.
There are some more limitations of our study. A reason for
underestimation of the prevalence of OAD could be that
eight patients did not bring back the PEF-meter with the
protocol. However, they assured that they had no prob-
lems any more. One could argue that the performance of
bronchoprovocation in a specialized centre would have
been the best gold standard to evaluate the accuracy of
spirometry in primary care and to distinguish between
COPD and asthma. As this was not available in general
practice, we tried to get as close as possible to the theoret-
ical gold standard [29]. In a highly selected clinical popu-
lation the measurement of PEF-variability within two
weeks had a smaller sensitivity and specificity than bron-
choprovocation [30]. However, the value of broncho-
provocation should not be over-estimated as a poor
agreement between bronchial hyper-reactivity and clinical
asthma was demonstrated in a review [31], and the corre-
lation between the clinical diagnosis asthma and bron-
choprovocation could be low [32]. Classical test
characteristics derived from hospital studies are of limited
value in primary care due to the lower incidence and
smaller extent of the particular disease found there [33].
Conclusion
The diagnostic accuracy of clinical signs and symptoms
was low as only self-reported wheezing had a significant
predictive value for the presence of OAD. The diagnostic
accuracy of CRP improved in combination with dyspnea
and smoking history. CRP was associated with the severity
of dyspnea as well as FEV1 and FIV1. Furthermore, CRP
increased with the number of pack years. Altogether, these
parameters might allow risk stratification of patients with
OAD in primary care. Further studies need to be done to
confirm these findings.
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